MedTrace Logo

Effect of Autologous Cord Blood Mononuclear Cells for Digestive System in Preterm Neonates

NCT05138276 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-04-25

No results posted yet for this study

Summary

Pre-clinical animal studies provide robust evidence regarding the beneficial effect of stem cells for intestinal disease.

This single-center, randomized, controlled, blinded trial assessed the effect of a single intravenous infusion of autologous cord blood MNCs (ACBMNCs) in preventing NEC in preterm neonates,and influence on growth and development.

Conditions

  • Neonatal Necrotizing Enterocolitis
  • Growth and Development
  • Preterm Infants
  • Nutrition

Interventions

OTHER

Autologous Umbilical Cord Blood Mononuclear Cells Therapy

Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of NEC

DRUG

0.9% Sodium Chloride

0.9% Sodium Chloride in control group

Sponsors & Collaborators

  • Guangdong Women and Children Hospital

    lead OTHER

Principal Investigators

  • Jie Yang, PHD · Guangdong Women and Children Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
26 Weeks
Max Age
32 Weeks
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05138276 on ClinicalTrials.gov